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Abstract
Background: Most epidemiological studies exploring the association between smokeless tobacco (SLT) use and coronary
heart disease (CHD) have been in Western populations, and have focused on SLT products used in those countries. Few
studies come from South Asian countries. Our objective was to determine the association between SLT use and CHD among
non-smoking adults in Bangladesh.
Methods: A matched case-control study of non-smoking Bangladeshi adults aged 40–75 years was conducted in 2010.
Incident cases of CHD were selected from two cardiac hospitals. Community controls, matched to CHD cases, were selected
from neighbourhoods, and hospital controls were selected from outpatient departments of the same hospitals. The Rose
Angina Questionnaire (RAQ) was also used to re-classify cases and controls.
Results: The study enrolled 302 cases, 1,208 community controls and 302 hospital controls. Current use was higher among
community controls (38%) compared to cases (33%) and hospital controls (32%). Current use of SLT was not significantly
associated with an increased risk of CHD when community controls were used (adjusted OR 0.87, 95% CI 0.63–1.19), or
when hospital controls were used (adjusted OR 1.00, 95% CI 0.63–1.60), or when both control groups were combined
(adjusted OR 1.00, 95% CI 0.74–1.34). Risk of CHD did not increase with use of individual types except gul, frequency,
duration, past use of SLT products, or using the RAQ to re-classify cases and controls. There was a significant association
between gul use and CHD when both controls were combined (adjusted OR 2.93, 95% CI 1.28–6.70).
Conclusions: There was no statistically significant association between SLT use in general and CHD among non-smoking
adults in Bangladesh. Further research on the association between gul use and CHD in Bangladesh along with SLT use and
CHD in other parts of the subcontinent will guide public health policy and interventions that focus on SLT-related diseases.
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Introduction
Smokeless tobacco (SLT), commonly used in many countries
[1], is associated with various health effects. Epidemiological
studies have consistently reported a significant positive association
between SLT use and cancers of various organs such as
oropharynx, oesophagus, stomach, pancreas, and lungs amongst
others [2]. Studies also report a positive association between SLT
use and oral diseases, dental diseases, hypertension, diabetes, poor
reproductive outcomes, addiction, and all-cause mortality [2].
A number of studies have also reported a significant positive
association between SLT use and risk factors for cardiovascular
diseases (CVD) such as raised blood pressure and a less healthy
lipid profile [3,4]. However, the results of epidemiological studies
assessing the association between SLT use and CHD, stroke or
CVD in general are inconsistent [5,6]. While several cohort [7,8,9]
and case-control studies [10,11] have reported a significant
positive association, other sufficiently powered cohort [12,13,14]
and case-control studies [15,16,17] have not reported such an
association. Some studies undertaken in Western countries
(Sweden and USA) have found an association [7,8,9] whereas
others have not [12,13,14]. South Asian SLT products differ from
Western products in terms of constituents, nicotine concentration,
manufacturing, and storage methods [18]. Usage patterns are also
likely to be different and may explain the different results from
studies conducted across various settings [6,19].
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There are a limited number of studies from South Asian
countries focusing on the association between SLT use and CHD.
One Indian cohort study [20] and another multinational case-
control study (INTERHEART) involving 52 countries [10]
reported a significant positive association and did include South
Asian SLT products. However, betel-quid and areca-nut were
included as SLT products although these products do not contain
tobacco. In addition, the INTERHEART study did not report
results separately for any South Asian country [10]. A small
number of Taiwanese studies [21,22,23] found a significant
positive association between betel-quid chewing and CHD, but
not with SLT use. The only study which has included SLT
products available in Bangladesh [11], all of which contain
tobacco, showed a significant positive association between SLT use
and CHD (adjusted odds ratio 2.2, 95% confidence interval 1.1–
4.5) and was conducted by the first author.
As a developing country in South-East Asia, Bangladesh has
high rates of smoking and SLT usage. Half of those aged $15
years (43%<41 million) use tobacco in some form [24]. The
prevalence of SLT use has been estimated as 27% with similar
rates in men (26%) and women (28%), but more prevalent in rural
areas (29%) compared to urban areas (23%) [24]. Whilst a number
of studies in Bangladesh have examined tobacco use [25,26,27],
the only study focusing on the SLT-CHD association [11] had a
small sample size (n = 207), included smokers, and recruited cases
and controls from a hospital setting.
Betel-leaf (paan) chewing is a cultural tradition of Bangladeshi
people extending back many centuries [28]. In Bangladesh, as in
other countries of the subcontinent, people chew betel-leaf with/
without SLT products routinely at various cultural and social
events [29]. As there has been no large systematic study conducted
in the Subcontinent, and the results of studies conducted in
Western settings are inconsistent [6], we conducted the current
study to determine whether there was any association between
SLT use and CHD among non-smoking adults in Bangladesh.
Methods
Ethics statement
Informed written consent was requested from each participant
in the prescribed consent form. Privacy and confidentiality were
maintained regarding the collected data. The protocol including
the information sheet and consent forms for this project was
approved by The University of Adelaide Human Research Ethics
Committee, Australia (H-117-2009) and the local ethics committee
of Bangladesh Medical Research Council, Bangladesh (BMRC/
NREC/2007–2010/125).
Study design and study sites
A matched case-control study was conducted in 2010. Data were
collected through structured interviews. CHD cases were recruited
from inpatient facilities of the National Institute of Cardiovascular
Diseases (NICVD) and the National Heart Foundation Hospital and
Research Institute (NHFH&RI), Dhaka, Bangladesh. Both hospitals
are accessible to people from all socio-economic groups as minimal
costs are associated with cardiac care. During the recruitment
period, approximately 550 patients per day were admitted to the six
cardiovascular units of NICVD and 110 patients per day were
admitted to the seven cardiovascular units of NHFH&RI. Four
hundred patients per day and 75 patients per day attended the
outpatient facilities of the NICVD and the NHFH&RI respectively.
Both hospital controls and community controls were selected in this
study in order to assess whether results differed according to the use
of different control groups. Hospital controls were recruited amongst
individuals attending cardiac outpatient facilities of the NICVD and
the NHFH&RI, while community controls were recruited from the
neighbourhood households of CHD cases within Dhaka City
Corporation (DCC) areas.
Study population
Inclusion criteria were: age 40–75 years, non-smoker, residence
within DCC areas, and well enough to undertake a 20 minute
interview. Non-smokers were defined as either (i) never smokers or
(ii) ex-smokers who had not smoked a single puff in the past 10
years. This was because most studies suggest that the maximum
reduction in CHD risk occurs within 4–14 years following smoking
cessation [30,31,32]; and from a practical perspective, only
including never smokers would have been difficult.
CHD cases
CHD patients admitted to the two hospitals and diagnosed as
incident cases of CHD (diagnosis for the first time within the
preceding twelve months) by hospital cardiologists, were selected
as cases. Cardiologists diagnosed CHD cases based on clinical
judgment (a combination of classical symptoms with positive
results from electrocardiogram, cardiac enzymes, exercise toler-
ance test, or coronary artery angiogram). Either angina and/or
myocardial infarction were included in the definition of CHD for
the purpose of this study.
Community controls
Neighbourhood residents of the CHD cases, who had no self-
reported cardiac disease, were selected as community controls.
Control subjects were matched by age (65 years), sex and socio-
economic status (SES) to the corresponding case. If a suitable
control subject could not be located in a suburb of the CHD case,
the next adjacent suburb was used (this happened in 28% of cases).
Hospital controls
Hospital controls were also used in this study. This was to
determine whether any systematic bias existed in the use of hospital
controls as is often postulated in the literature [33,34]. These
additional analyses are not the focus of this particular article and will
be presented elsewhere. Patients, who attended cardiac outpatient
facilities of the same hospitals and were diagnosed as not suffering
from CHD by hospital cardiologists, were selected as hospital
controls. It should be noted that unlike a developed country, many
individuals with symptoms of chest pain or breathlessness attend
outpatient facilities of cardiac hospitals for screening of cardiac
disease; either self-referred or referred by a general practitioner in
Bangladesh. About two-thirds (64%) of the hospital controls were
selected from the hypertension clinic of NHFH&RI, which was the
only available source of recruiting controls in that study setting. This
poses a risk of potential bias because SLT use is known to be
associated with hypertension [3]. Diagnoses for these patients
included hypertension (62%), non-specific chest pain (48%), and
gastric hyper-acidity (13%). Some patients were not assigned a
diagnosis, and symptoms of palpitation (10%) or breathlessness (8%)
were given in the case-notes. Each hospital control was matched
with a corresponding case by age (65 years) and sex.
Cases and controls re-classified by the Rose Angina
Questionnaire (RAQ)
In addition to our study definition of cases and controls, we also
used the RAQ [35] to re-classify study participants into RAQ cases
and RAQ controls. Individuals responding affirmatively to the
RAQ were re-classified as RAQ cases and the negative responders
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were re-classified as RAQ controls as shown in Figure 1. It is to be
noted that the RAQ cases and the RAQ controls were not matched.
Sample size
Sample size was calculated using Epi-info version 3.5.1. With
95% confidence intervals, 80% power, a control: case ratio of 4:1,
a correlation for matched design of 0.1, an expected frequency of
SLT use among controls of 25% [25], and a clinically significant
odds ratio considered to be 1.5 [11,20], 302 cases and 1,208
controls were required for this study. Additionally, one hospital
control was selected for each case (302 additional controls).
Study tool
A structured interview was conducted to measure exposure and
confounding variables. Initially, a screening questionnaire was used
to select eligible cases and controls. This included information on
age, residence, smoking and heart disease status. Once informed
consent was obtained, participants were asked a range of questions
covering socio-demographic information, a detailed history of SLT
use, and other known risk factors for CHD. Socio-demographic
information included age, gender, marital status, highest level of
education achieved, primary occupation and monthly house-rent as
a proxy to socio-economic status.
Betel-leaf or areca-nut alone was not included as a SLT
product, as they do not contain tobacco. If a respondent used any
SLT product with/without betel-leaf or areca-nut in the last
twelve months, he/she was categorized as a current SLT user. If a
respondent ceased using SLT products for at least last twelve
months, he/she was categorized as a past SLT user. If a
respondent was not using any SLT product currently or in the
past, he/she was categorized as never a tobacco user (as they were
also non-smokers according to the participant selection criteria).
Using frequency and duration of SLT use, we categorized
frequency into light use (less than once a day) and heavy use (at
least once a day), duration into short duration (,10 years) and
long duration (.10 years), and quit duration into short-term quit
(2–10 years) and long-term quit (.10 years).
Information on known risk factors for CHD included self-
reported history of hypertension, diabetes, family history of heart
disease, level of physical activity, use of hormonal contraceptives
for women, exposure to indoor passive smoking, and occurrence of
acute psycho-social events within last one year.
Data collection
Reasons for non-participation were documented. If participants
asked whether SLT could cause any health effect, interviewers
Figure 1. Re-classification of cases and controls using the Rose Angina Questionnaire (RAQ).
doi:10.1371/journal.pone.0030584.g001
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only provided this information at the completion of the interview.
Categorization of CHD cases according to the case definition and
the RAQ was undertaken by the first author and selection of the
majority of controls was undertaken in his presence. The first
author trained the interviewers and undertook regular supervision
of all data collection activities. In addition, the first author re-
interviewed 4 cases (1%), 24 community controls (2%) and 6
hospital controls (2%) as a means of quality control of data
collection.
Laboratory analysis
To enhance interpretation of the study results, samples of SLT
products most commonly used within the DCC areas, were tested
for nicotine. Purchased samples of paan-masala (3 samples), jarda (1
sample), and gul (1 sample) were analysed following extraction,
steam distillation and silicotungstic acid gravimetric method [36]
at the Institute of Food Science and Technology (IFST),
Bangladesh Council of Scientific and Industrial Research
(BCSIR). Nicotine concentration was reported in percentage by
weight (% by wt.). Sada-pata, which is the natural tobacco leaf in
dried form, was also used by study participants but was not tested
for nicotine because of the natural variation of this product. A
recent surveillance study reported nicotine concentrations in
Bangladeshi sada-pata as 1.97% [37].
Data analysis
Analyses were performed using STATA version 10 statistical
software. Initially, categorical variables were described as
proportions for socio-demographic variables, SLT use, and risk
factors for CHD. To determine the association between SLT use
and CHD, cases and controls were compared using cross-
tabulations at first. To statistically compare cases and controls,
we used McNemar’s chi-squared (x2) tests when the frequency in
all of the cells of the cross-tabulation was $5 and Fisher’s exact
test otherwise. Univariate conditional logistic regression models
[38] were fitted to determine the strength of the association
between SLT use and CHD, with the effect of SLT use expressed
as a matched odds ratios (ORs) with 95% confidence intervals
(CIs). Then multivariate conditional logistic regression models
were fitted to adjust for potential confounding variables. The most
important confounder is the presence of hypertension; this is
particular so with analysis using only hospital controls. Confound-
ing variables were identified initially using a x2 test relating the
variables to CHD. If the p-value from the x2 test was less than 0.20
and there was no missing data for the confounder, that variable
was included into the final multivariate analysis. The adjusted
ORs with 95% CIs finally determined the association between
SLT use and CHD in this study. To determine whether the
inclusion of ex-smokers could have biased the results, analyses
were conducted separately for never-smokers, ex-smokers, and
combining both groups. Data were analysed separately using
community controls, hospital controls, and combining both
control groups. We also analysed data with all groups of re-
classified cases and controls done by the RAQ to further explore
the association between SLT use and CHD (Figure 1). As the
RAQ cases and the RAQ controls were not matched, we used
univariate and multivariate logistic regression models for these
analyses.
Results
Study participants
Eligible participants included 311 hospital cases, 1293 commu-
nity controls and 316 hospital controls. Nine potential hospital
cases (3%), 85 potential community controls (7%), and 14 potential
hospital controls (4%) did not consent to participate. Thus, the
overall response rate was 94%. Results for the remaining 302
CHD cases from two cardiac hospitals, 1208 community controls
and 302 hospital controls are presented in this paper.
Mean age of participants was 53 years (standard deviation 68.5
years), 49.7% were men. Table 1 shows the distribution of
different socio-demographic variables among cases and controls,
and there were no significant differences in socio-demographic
variables comparing cases and controls. Amongst the 1812
participants, 1292 (71%) were never-smokers. Never-smoking
status was similar between cases (203 out of 302, 67%) and either
community controls (864 out of 1208, 72%) or hospital controls
(225 out of 302, 75%).
Risk factors for CHD
Table 1 shows the distribution of risk factors for CHD among
cases and controls. More than two-thirds of hospital controls (67%)
were hypertensive compared to half of cases (60%) and one-third
of community controls (34%).The majority of these hospital
controls were selected from the hypertension clinic of one study
hospital which explains this difference.
Nicotine content of the SLT products
Nicotine was absent in all three commercial samples of paan-
masala products tested. The selected samples of jarda and gul
contained 0.96% and 5.48% nicotine respectively. Therefore, our
data analysis included only three types of SLT products containing
nicotine: jarda, sada-pata (1.97% nicotine) and gul.
Use of SLT products
Amongst the 1812 participants, 648 (36%) were current SLT
users. Current use was higher among community controls (38%)
compared to that of cases (33%) and hospital controls (32%).
Quitting was more common among cases compared to either
group of controls. Amongst the never-smoker participants, current
use of SLT was more common among community controls (35%)
than that of cases (25%) and hospital controls (30%). Amongst the
ex-smoker participants, ever use, current use and quitting of SLT
products were more common among cases compared to either
group of controls. Table 2 shows the status of SLT use among the
study participants.
Amongst the individual types of SLT products, use of jarda was
more common compared to sada-pata and gul. Current use of jarda
was slightly higher among community controls (26%) compared to
either cases (21%) or hospital controls (24%). There was no
difference between cases and controls for current use of sada-pata.
Current use of gul was slightly more common among cases (5%)
compared to either group of controls (2%). The majority of
exclusive jarda, sada-pata or gul consumers were heavy users and
long duration users. Mean duration of jarda use was 16 years (0.1–
55 years), sada-pata 28 years (3–60 years), and gul 17 years (0.5–45
years). There was no difference between cases and controls for
heavy use or long duration use of each SLT product.
Association between SLT use and CHD
Table 2, 3, 4 show the results of univariate and multivariate
analyses. Among the socio-demographic variables and risk factor
variables for CHD, age, hypertension, diabetes, and acute psycho-
social stress were significantly associated with CHD when data
were analysed using community controls, hospital controls or both
controls. In addition, marital status and indoor passive smoking
were significantly associated with CHD when data were analysed
Smokeless Tobacco and Coronary Heart Disease
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with hospital controls. There was no statistically significant
association between current SLT use and CHD when community
controls were used (adjusted OR 0.87, 95% CI 0.63–1.19), or
hospital controls were used (adjusted OR 1.00, 95% CI 0.63–
1.60), or when both controls were combined (adjusted OR 1.00,
95% CI 0.74–1.34). There was no association between ever use or
cessation of SLT usage and CHD. Similar results were found
when data were analysed separately for never-smokers and ex-
smokers. Similarly, Table 3 shows that there was no statistically
significant association between SLT use and CHD, when data
were analysed using the RAQ classified cases and RAQ classified
controls.
When we stratified our analyses according to younger (40–57
years) and older (58–75 years) age groups, there was no statistically
significant association between current SLT use and CHD among
younger and older participants, when community controls were
used (younger: adjusted OR 1.08, 95% CI 0.73–1.60, older:
adjusted OR 0.54, 95% CI 0.27–1.07), or hospital controls were
used (younger: adjusted OR 1.14, 95% CI 0.59–2.19, older:
adjusted OR 0.89, 95% CI 0.32–2.47), or when both controls were
combined (younger: adjusted OR 1.19, 95% CI 0.82–1.72, older:
adjusted OR 0.75, 95% CI 0.42–1.32). Results did not change
when data were analysed separately for never-smokers and ex-
smokers.
When we stratified our analyses further according to gender,
there was no statistically significant association between current
SLT use and CHD among men and women, when community
controls were used (men: adjusted OR 1.30, 95% CI 0.81–2.10,
Table 1. Socio-demographic and risk factor variables for coronary heart disease (CHD) among the study participants.
Socio-demographic variables Total, N (%) Cases, n(%)
Community
Controls, n(%)
Hospital controls,
n(%)
Total study participants 1812 302 1208 302
Age in years, mean (SD) 53.0 (68.5) 53.5 (68.5) 53.1 (68.5) 51.9 (68.4)
Male participants 900 (49.7) 150 (49.7)a 600 (49.7)a 150 (49.7)a
Married (and living with spouse) 1414 (78.0) 232 (76.8)a 939 (77.8)a 243 (80.5)a
Highest level of education achieved
Illiterate 204 (11.3) 34 (11.3)a 151 (12.5)a 19 (6.3)a
Can sign names 212 (11.7) 27 (8.9)a 150 (12.4)a 35 (11.6)a
Primary 527 (29.1) 95 (31.5)a 338 (28.0)a 94 (31.2)a
Secondary 239 (13.2) 44 (14.6)a 153 (12.7)a 42 (14.0)a
Higher-secondary 197 (10.9) 33 (10.9)a 116 (9.6)a 48 (15.9)a
Above higher-secondary 418 (23.1) 66 (21.9)a 290 (24.0)a 62 (20.6)a
Primary occupation
Service holder 558 (30.8) 87 (28.8)a 369 (30.6)a 102 (33.8)a
Businessmen 262 (14.5) 42 (13.9)a 180 (14.9)a 40 (13.2)a
Housewife 741 (40.9) 126 (41.7)a 495 (41.0)a 120 (39.7)a
Retired 235 (13.0) 47 (15.6)a 149 (12.3)a 39 (12.9)a
Socio-economic status (SES) by monthly house-rent (HR)
Lower SES (HR,5000 BDT) 656 (36.2) 109 (36.1)a 433 (35.8)a 114 (37.7)a
Middle SES (HR 5000–10000 BDT) 930 (51.3) 152 (50.3)a 620 (51.3)a 158 (52.3)a
Higher SES (HR.10000 BDT) 226 (12.5) 41 (13.6)a 155 (12.8)a 30 (9.9)a
Presence of other risk factors for CHD
Hypertensiona 796 (43.9) 180 (59.6)a 413 (34.2)b 203 (67.2)a
Diabetesb 446 (24.6) 129 (42.7)a 244 (20.2)b 73 (24.2)b
Family history of heart disease 421 (23.2) 94 (31.5)a 248 (21.5)b 79 (27.2)a
Undertook physical activityc 1116 (61.6) 179 (59.5)a 788 (65.3)b 149 (50.2)b
Use of hormonal contraceptives 60 (3.3) 9 (3.0)a 41 (3.4)a 10 (3.3)a
Exposure to indoor passive smokingd 321 (17.7) 58 (19.2)a 218 (18.0)a 45 (14.9)a
Acute psycho-social stresse 434 (24.0) 94 (31.1)a 265 (21.9)b 75 (24.8)a
Superscripts indicate which categories show a statistically significant (p,0.05) difference using chi-squared tests between cases and controls: same letter indicates no
difference, different letter indicates a difference.
a‘‘Have you ever been told by a doctor or a health-worker that you have raised blood-pressure or hypertension?’’
b‘‘Have you ever been told by a doctor or a health-worker that you have raised blood-glucose or diabetes?’’
cPhysical activity included moderate to vigorous physical activity for at least 30 minutes per week which made them huff and puff (where they can still talk but can’t
sing). There were three levels of physical activity: mild (1–2 times/week), moderate (3–4 times/week) and vigorous ($5 times/week). All these three levels were
combined together in this table.
d‘‘Does anyone smoke inside the same room, where you live?’’
eSuch an incident that caused mental agony, sorrow, unhappiness or anxiety within last one year, like death of family members, divorce, separation, sudden job loss,
unemployment, financial loss etc.
doi:10.1371/journal.pone.0030584.t001
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women: adjusted OR 0.62, 95% CI 0.38–0.99), or hospital
controls were used (men: adjusted OR 1.08, 95% CI 0.46–2.55,
women: adjusted OR 0.84, 95% CI 0.42–1.68), or when both
controls were combined (men: adjusted OR 1.36, 95% CI 0.88–
2.09, women: adjusted OR 0.73, 95% CI 0.47–1.14). Results did
not change when data were analysed separately for never-smokers
and ex-smokers.
Table 4 shows that there was no statistically significant
association between use of jarda or sada-pata and CHD for current
use, quitting or ever use during analyses by different control
groups or by different smoking status. However, the product
containing highest amount of nicotine (5.48%) in this study, gul,
showed a significant positive association with CHD (adjusted OR
2.93, 95% CI 1.28–6.70), when data were analysed using both
groups of controls.
There was no statistically significant association between
frequency or duration of each SLT product use and CHD, except
use of gul. There was a significant positive association between
heavy use of gul and CHD (adjusted OR 2.78, 95% CI 1.17–6.57),
and long duration use of gul and CHD (adjusted OR 3.57, 95% CI
1.26–10.1) when both controls were used. There may have been a
problem with lack of power to make stratified analyses with each
SLT product to identify the association with CHD, as there were
very few users of each SLT product in this study (Table 4).
Discussion
In this study, there was no statistically significant association
between SLT use in general and CHD among non-smoking adults
in Bangladesh. However, there was a significant association
between use of gul and CHD. This is very important because whilst
in general our study did not find an association between SLT use
and CHD, if nicotine content is higher in SLT (as it is in some
other countries), it is likely to pose a significant risk for the
development of CHD. No significant association was found for
frequency or duration of each SLT product except gul. Heavy use
and long duration of gul use was significantly associated with
CHD. Results did not change when community controls, hospital
controls, or both control groups were used during analyses, and
when never-smoker, ex-smoker, or both groups were used. The
results were the same for current users, quitters or ever users of
SLT products. In addition, re-classification of cases and controls
utilizing the RAQ did not change the findings of association
between SLT use and CHD. Separate analyses with different age
groups and gender did not change the results as well.
Findings of this study are supported by earlier case-control
[15,16,17,39], cross-sectional [40] as well as cohort studies
[12,13,14,41,42]. None of these case-control studies conducted
in Sweden reported a statistically significant positive association
between use of snuff and CHD, although the findings were for
men only. Similar to case-control studies, none of these cohort
studies have reported a significant association between SLT use
and CHD. All of these cohort studies except the US study [12]
included men only. The US study [12], which considered only
fatal CHD, showed the same results when analysed separately for
men (adjusted hazard ratio 0.6, 95% CI 0.3–1.2) and women
(adjusted OR 1.4, 95% CI 0.8–2.2).
On the other hand, findings of this study are not supported by
other cohort [7,8,9,20] and case-control studies [10,11]. The
Swedish Construction Worker study [7] and the US Cancer
Prevention Study [8] involving a larger cohort reported a
significant positive association between SLT use and CHD.
However, it is to be noted that both of these studies included
men and fatal CHD only. Another US cohort study [9], which
included both sexes as well as fatal and non-fatal CHD, reported a
significant positive association between SLT use and CVD, but no
separate results were reported for fatal and non-fatal CVD, or for
CHD and stroke. All of these cohort studies included Western SLT
products and populations. The only South Asian cohort study,
conducted in India [20], showed a significant positive association
between use of Indian SLT products and CHD among women
(adjusted risk ratio 1.25, 95% CI 1.05–1.49), but not among men
(adjusted risk ratio 0.89, 95% CI 0.75–1.05). This is also in
contrast to what we have found in this study. The constituents of
Indian SLT products are likely to be different from Bangladeshi
SLT products, which could have resulted in the significant positive
association in the Indian study. The INTERHEART [10] and the
Bangladeshi case-control study [11] showed a significant positive
association between SLT use and non-fatal CHD. All of these
studies were limited by various methodological issues as described
in the introduction to this paper and elsewhere [6].
The literature suggests inconsistent evidence regarding the
association between SLT use and CHD among different age-
groups. We did not find any difference in results by age, which is
supported by another study that did not find any significant
association among younger (35–54 years) and older (55–64 years)
people [15]. On the other hand, whilst a cross-sectional study of
Swedish construction workers did not find a significant association
among younger workers (46–55 years) [40], the subsequent cohort
study reported a significant association among young (35–54 years)
as well as older workers (55–65 years) [7].
There was a significant association between use of gul and CHD
in this study, although the numbers were not large enough to
confirm this association from this study as mentioned before. Gul is
the mixture of tobacco powder, molasses, alkaline modifiers and
other ingredients prepared commercially, and used in other parts
of South Asia including Bangladesh [1,37]. This product is kept
between cheek and gum, used alone unlike other SLT products
which are usually used with betel leaf in Bangladesh. This product
was reported as having the highest nicotine concentration in this
study. A recent survey of SLT products from different countries
also reported higher nicotine concentration in Bangladeshi gul
compared to other SLT products [37]. Frequency and duration of
gul use was also significantly associated with CHD in the present
study. Further well-powered study need to explore the association
between this specific SLT product and CHD in a more detailed
way.
Results from the existing research in Western countries are
inconclusive; studies from South Asia are very limited and have
some methodological constraints [6]. The current study addressed
some of these methodological issues. Strengths of this study
comprise including only non-smoking participants, a wider age
range, both men and women, both community controls and
hospital controls, and including exclusive SLT products from
Bangladesh. Inclusion of non-smokers controlled for the potential
strong confounding effects of smoking on CHD at the design stage.
In addition, potential confounders were measured and adjusted
for. This was particularly important for hypertension, which had
the potential of introducing bias when data were analysed using
hospital controls. Increasing the age limit of the participants in
contrast to the earlier Bangladeshi case-control study helped assess
the association between SLT use and CHD among a broader and
more representative sample of Bangladeshi population. The
consistent findings regardless of using either hospital controls or
community controls support the accuracy of the study results. For
the exposure variable, betel-quid or areca-nut was not included as
a SLT product unlike other prior studies; rather selection of SLT
products was supported by direct analysis of nicotine content.
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Selecting subjects from the two tertiary care cardiac hospitals and
the catchment areas within the DCC, which include people from
all socio-economic strata, suggest our results are representative for
urban dwellers in Bangladesh. However, the issue of different
health care seeking behaviours should be kept in mind. Re-
interviewing a percentage of both cases and controls ensured the
quality of the collected data. Re-analysing data using the RAQ
classification strengthened the study findings because milder or as
yet undiagnosed CHD were identified from both hospitals and
communities in this study.
The lack of an association between SLT use in general and
CHD in this study can be explained in several ways. Nicotine
concentration of some Bangladeshi SLT products, specifically gul is
higher compared to commercial cigarettes (1.63%) or bidi smoking
(2.12%) [43]. But more gradual and least peaked dosing of
nicotine occurs for SLT use, although the blood concentration of
nicotine remains similar for a daily SLT user and a smoker [44].
On the other hand, rapid dosing of nicotine occurs with smoking
and this has the potential to result in much more intense
cardiovascular stimulation [45]. Finally, SLT products do not
contain carbon monoxide and polycyclic aromatic hydrocarbons,
which are known to contribute to the cardiovascular effects of
smoking [15,45]. A significant association between gul use and
CHD may be due to the higher nicotine concentration in the
product itself along with the rapid absorption from buccal cavity to
cause cardiovascular effects. It may also be due to other additives
in gul having cardiovascular effects. Further studies need to
confirm these hypotheses.
It was beyond the scope of this study to verify the self-reported
diagnosis of non-CHD among the community controls by a
qualified physician. Fatal CHD cases were not included in this
study, because hospital death registers in Bangladesh are not well
developed. In addition, collection of SLT exposure data from
family members of deceased individuals would be less reliable
compared to data collected from the users themselves. Reporting
of the stratified analyses with each SLT product in this study has
the potential to be biased as we had relatively small number of
specific SLT users. We could not measure the amount of different
SLT use from the study participants, as there are no standard pack
sizes unlike snus or snuff. This limited us from including the
amount during calculation of dose-response relationship between
SLT use and CHD. However, as there was no association between
SLT use and CHD, this missing information did not affect the
result of this study. There is a chance of having interviewer-bias in
this study, which can happen to any epidemiological study. But we
had a structured questionnaire and the interviewers were trained
to ask the exact question only, not try and interpret the questions
for the respondents. However, as the interviewers could not be
blinded, it is difficult to completely overcome this. Since our
subjects were recruited from within Dhaka, our results may not be
generalizable to the rural areas of Bangladesh. We attempted to
measure and adjust for as many possible confounding variables as
possible. Importantly, this included hypertension as previously
discussed. However, it was not possible to measure body mass
index (BMI) because we felt that urban dwellers in Bangladesh
would be unlikely to invite interviewers into their homes to
undertake height and weight measurements. Also, Bangladeshis do
not tend to measure their own weight on a regular basis and so
self-report data was also not considered feasible.
This study has implications for tobacco control policy. There is
an ongoing debate regarding the use of SLT products as a safer
alternative to active smoking and as a possible mechanism to
encourage smoking cessation [2]. On the other hand, there is a
concern that SLT use may potentiate tobacco smoking [46]. As
tobacco control policies vary strikingly between countries [47],
there is the potential of introducing Western SLT products as a
harm-reduction agent into developing countries of South Asia
[48]. Such products may contain ingredients, which could have
unknown deleterious effects on CHD and other health conditions.
In addition, SLT products and nicotine concentration also differ in
other South Asian countries such as in India or Pakistan [1,49].
This study did not find an association between SLT use in
general and CHD among non-smoking Bangladeshi adults. This is
the first large scale case-control study assessing the association
between SLT use and CHD from a South Asian perspective.
Despite the fact that the current study did not find an association
between different Bangladeshi SLT products and CHD except gul,
SLT use has an established risk for development of cancers and of
dental diseases. Tobacco control campaigns should focus on these
SLT-related diseases. Given the fact that the burden of tobacco-
related illnesses are more among people of lower socio-economic
status [25], as well as limited resources for health promotion
activities in developing countries, policies supporting non-use of
any form of tobacco are justified. Further research on the
association between gul use and CHD in Bangladesh, along with
SLT use and CHD in other parts of the subcontinent where SLT
products may differ will guide public health policy and
interventions to prevent SLT-related diseases. Because SLT use
is not harmless, the strategic focus should be upon controlling both
smoking and SLT use in Bangladesh.
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